Similar articles

• Response to inhaled bronchodilators in COPD.

  Anthonisen NR, Wright EC. Anthonisen NR, et al. Chest. 1987 May;91(5 Suppl):36S-39S. Chest. 1987. PMID: 2882959 Clinical Trial. No abstract available.
• Bronchodilator therapy of COPD. A reanalysis suggests new roles and new concerns.

  Deffebach ME. Deffebach ME. Chest. 1996 Jul;110(1):5-6. doi: 10.1378/chest.110.1.5. Chest. 1996. PMID: 8681663 No abstract available.
• Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

  Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Rennard SI, et al. Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92. doi: 10.1164/ajrccm.163.5.9903053. Am J Respir Crit Care Med. 2001. PMID: 11316640 Clinical Trial.
• Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

  Cazzola M, Donner CF. Cazzola M, et al. Drugs. 2000 Aug;60(2):307-20. doi: 10.2165/00003495-200060020-00005. Drugs. 2000. PMID: 10983735 Review.
• Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

  Jarvis B, Markham A. Jarvis B, et al. Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006. Drugs Aging. 2001. PMID: 11419918 Review.